Headlines

© Getty Images

Phathom Pharmaceuticals receives FDA approval for Voquenza to treat non-erosive GERD

Phathom Pharmaceuticals, Inc.dedicated to developing and commercializing treatments for gastrointestinal (GI) diseases, announced today that the US Food and Drug Administration (FDA) has approved Voquenza (vonoprazan) 10mg tablets for the relief of heartburn associated with non-erosive gastroesophageal reflux disease (non-erosive GERD) in adults.

Global Industry News

Trends

Spotlight

Follow us

Webinars

Featured Suppliers

All